Tempo Pharmaceuticals is positioned to be a leader in the emerging field of nanopharmaceuticals. Nanotechnology has the potential to transform drug therapy over the next decade, significantly improving the efficacy and safety of existing, well established drugs as well as new drugs. With these advancements comes the potential to achieve cures and improve the lives of patients where it was not previously possible.

The Company has assembled an all-star team consisting of management, founders, board of directors, investors, and scientific advisory board with great success in building companies and developing and commercializing important products.

Tempo is pursuing three key elements of its strategy to achieve leadership in nanopharmaceuticals. First, the Company is focused on achieving rapid and clinically significant human proof of concept with its technology. Second, the Company is building a deep and diversified product pipeline, leveraging its proprietary nanotechnology platform. Finally, Tempo will pursue a hybrid business model, retaining certain key products for development and commercialization to achieve full company value creation, while at the same time collaborating on other products to leverage the resources and capabilities of partners.